Mavyret (Glecaprevir/Pibrentasvir) Patent Expiration, LOE Window & CMS Spending

Mavyret (Glecaprevir/Pibrentasvir) by AbbVie: FDA Orange Book core substance LOE 2035-12-05 (last listed 2036-12-24), 0 AB generics, $768.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN209394 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-12-05
Last Listed Patent or Exclusivity Date2036-12-24
Orange Book Patents (*PED Extensions)20 patents (10 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$768.3M
2024 Medicare Part D Spend$165.3M
2024 Medicaid Spend$602.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.